New progress on diagnosis and treatment of anorectal malignant melanoma

doi:10.3760/cma.j.cn371439-20191216-00040

Abstract

Abstract:

Anorectal malignant melanoma (ARMM) is a rare malignant melanoma arising from mucosa in anorectal area. Symptoms and signs of ARMM are not specific, causing high misdiagnosis rate in this disease. Cornerstone treatment of ARMM is radical excision. Although more systematic therapy including target therapy and immunotherapy have been applied to ARMM, as the understanding of ARMM deepens. The overall prognosis of ARMM is still poor due to the lack of accurate clinical classification and staging standards.

Key words: Melanoma, Rectum, Anal canal, Diagnosis, Therapy

Zhang Ruizhi, Chen Xin, Zhang Peng, Tao Kaixiong. New progress on diagnosis and treatment of anorectal malignant melanoma[J]. Journal of International Oncology, 2020, 47(6): 377-380.

References 30

[1]	Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma[J]. Lancet, 2018,392(10151):971-984. DOI: 10.1016/S0140-6736(18)31559-9. doi: 10.1016/S0140-6736(18)31559-9 pmid: 30238891
[2]	Fields AC, Goldberg J, Senturk J, et al. Contemporary surgical management and outcomes for anal melanoma: a national cancer database analysis[J]. Ann Surg Oncol, 2018,25(13):3883-3888. DOI: 10.1245/s10434-018-6769-y. doi: 10.1245/s10434-018-6769-y pmid: 30209727
[3]	Naqvi J, Lee A, Lederman A, et al. Patterns of care and survival outcomes in the treatment of anal melanoma[J]. J Gastrointest Cancer, 2020,51(1):211-216. DOI: 10.1007/s12029-019-00238-5. doi: 10.1007/s12029-019-00238-5 pmid: 30982929
[4]	Ren M, Lu Y, Lv J, et al. Prognostic factors in primary anorectal melanoma: a clinicopathological study of 60 cases in China[J]. Hum Pathol, 2018,79:77-85. DOI: 10.1016/j.humpath.2018.05.004. doi: 10.1016/j.humpath.2018.05.004 pmid: 29763716
[5]	Nam S, Kim CW, Baek SJ, et al. The clinical features and optimal treatment of anorectal malignant melanoma[J]. Ann Surg Treat Res, 2014,87(3):113-117. DOI: 10.4174/astr.2014.87.3.113. doi: 10.4174/astr.2014.87.3.113
[6]	Manabe S, Boku Y, Takeda M, et al. Endoscopic submucosal dissection as excisional biopsy for anorectal malignant melanoma: a case report[J]. World J Clinl Cases, 2019,7(13):1652-1659. DOI: 10.12998/wjcc.v7.i13.1652.
[7]	Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, et al. Extracutaneous melanomas: a primer for the radiologist[J]. Insights Imaging, 2015,6(6):707-717. DOI: 10.1007/s13244-015-0427-8. doi: 10.1007/s13244-015-0427-8 pmid: 26334521
[8]	Park HJ, Kim HJ, Park SH, et al. JOURNAL CLUB: primary anorectal melanoma: MRI findings and clinicopathologic correlations[J]. AJR Am J Roentgenol, 2018,211(2):W98-W108. DOI: 10.2214/AJR.17.18807. doi: 10.2214/AJR.17.18807 pmid: 29927334
[9]	Wang S, Sun S, Liu X, et al. Endoscopic diagnosis of primary anorectal melanoma[J]. Oncotarget, 2017,8(30):50133-50140. DOI: 10.18632/oncotarget.15495. doi: 10.18632/oncotarget.15495 pmid: 28412758
[10]	Zou S, Cheng Z, Song S, et al. Anal malignant melanoma manifesting hepatic metastases shown on FDG PET/CT[J]. Clin Nucl Med, 2018,43(5):386-388. DOI: 10.1097/RLU.000000000000-2056. doi: 10.1097/RLU.0000000000002056 pmid: 29517546
[11]	Falch C, Mueller S, Kirschniak A, et al. Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with ¹⁸F-FDG-PET/CT[J]. World J Surg Oncol, 2016,14(1):185. DOI: 10.1186/s12957-016-0938-x. doi: 10.1186/s12957-016-0938-x pmid: 27422527
[12]	Valpione S, Gremel G, Mundra P, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients[J]. Eur J Cancer, 2018,88:1-9. DOI: 10.1016/j.ejca.2017.10.029. doi: 10.1016/j.ejca.2017.10.029 pmid: 29175734
[13]	Chen H, Cai Y, Liu Y, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis[J]. Medicine (Baltimore), 2016,95(7):e2770. DOI: 10.1097/MD.0000000000002770. doi: 10.1097/MD.0000000000002770
[14]	Ford MM, Kauffmann RM, Geiger TM, et al. Resection for anal melanoma: is there an optimal approach?[J]. Surgery, 2018,164(3):466-472. DOI: 10.1016/j.surg.2018.05.026. doi: 10.1016/j.surg.2018.05.026 pmid: 30041967
[15]	Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review[J]. Ann Surg, 2015,261(4):670-677. DOI: 10.1097/SLA.0000000000000862. doi: 10.1097/SLA.0000000000000862 pmid: 25119122
[16]	Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma[J]. Eur J Cance, 2014,50(1):121-127. DOI: 10.1016/j.ejca.2013.09.007.
[17]	Mignard C, Deschamps Huvier A, Gillibert A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma[J]. J Oncol, 2018,2018:1908065. DOI: 10.1155/2018/1908065. doi: 10.1155/2018/1908065 pmid: 30631354
[18]	Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma[J]. Cancer, 2016,122(21):3354-3362. DOI: 10.1002/cncr.30259. doi: 10.1002/cncr.30259 pmid: 27533633
[19]	Dodds TJ, Wilmott JS, Jackett LA, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases[J]. Pathology, 2019,51(1):39-45. DOI: 10.1016/j.pathol.2018.09.060. doi: 10.1016/j.pathol.2018.09.060 pmid: 30497801
[20]	Sakaizawa K, Ashida A, Uchiyama A, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients[J]. J Dermatol Sci, 2015,80(1):33-37. DOI: 10.1016/j.jdermsci.2015.07.012. doi: 10.1016/j.jdermsci.2015.07.012 pmid: 26282084
[21]	Gong HZ, Zheng HY, Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis[J]. Melanoma Res, 2018,28(4):259-270. DOI: 10.1097/CMR.0000000000000454. doi: 10.1097/CMR.0000000000000454 pmid: 29746316
[22]	Cinotti E, Chevallier J, Labeille B, et al. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases[J]. J Eur Acad Dermatol Venereology, 2017,31(11):1834-1840. DOI: 10.1111/jdv.14353.
[23]	Schaefer T, Satzger I, Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis of 75 patients[J]. Medicine (Baltimore), 2017,96(1):e5753. DOI: 10.1097/MD.0000000000005753. doi: 10.1097/MD.0000000000005753
[24]	Wei X, Mao L, Chi Z, et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study[J]. Oncol Res, 2019,27(4):495-501. DOI: 10.3727/096504018X-15331163433914. doi: 10.3727/096504018X15331163433914 pmid: 30075827
[25]	Buchbinder EI, Sosman JA, Lawrence DP, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma[J]. Cancer, 2015,121(22):4007-4015. DOI: 10.1002/cncr.29622. doi: 10.1002/cncr.29622 pmid: 26264378
[26]	Kalinsky K, Lee S, Rubin KM, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage Ⅳ mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)[J]. Cancer, 2017,123(14):2688-2697. DOI: 10.1002/cncr.30663. doi: 10.1002/cncr.30663 pmid: 28334439
[27]	Alrwas A, Papadopoulos NE, Cain S, et al. Phase Ⅰ trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma[J]. Melanoma Res, 2014,24(4):342-348. DOI: 10.1097/CMR.0000000000000062. doi: 10.1097/CMR.0000000000000062
[28]	Heppt MV, Roesch A, Weide B, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma[J]. Eur J Cancer, 2017,81:36-44. DOI: 10.1016/j.ejca.2017.05.014. doi: 10.1016/j.ejca.2017.05.014 pmid: 28600969
[29]	Cui C, Lian B, Zhou L, et al. Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients[J]. Ann Surg Oncol, 2018,25(8):2184-2192. DOI: 10.1245/s10434-018-6503-9. doi: 10.1245/s10434-018-6503-9 pmid: 29748886
[30]	Chae WY, Lee JL, Cho DH, et al. Preliminary suggestion about staging of anorectal malignant melanoma may be used to predict prognosis[J]. Cancer Res Treat, 2016,48(1):240-249. DOI: 10.4143/crt.2014.305. doi: 10.4143/crt.2014.305 pmid: 25761474